Stock ADMA ADMA BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
10.47 USD -1.04% Intraday chart for ADMA Biologics, Inc. +9.63% +131.64%
May. 10 HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating MT
May. 10 Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Glancy Prongay & Murray LLP Announces the Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Adamas Pharmaceuticals, Inc. - ADMS
PR
Adma Biologics: Q1 Earnings Snapshot
AQ
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
GL
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
GL
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
GL
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
GL
Adma Biologics: Q4 Earnings Snapshot
AQ
ADMA Biologics Announces CFO Transition
GL
ADMA Biologics Announces CFO Transition
AQ
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
GL
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
AQ
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
GL
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
GL
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
AQ
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
GL
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
GL
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
GL
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADMA Stock
  4. News ADMA Biologics, Inc.
  5. Press Releases